caa a22 4500 469116439 CHVBK 20180323133126.0 cr unu---uuuuu 170328e19920201xx s 000 0 eng 10.1007/BF00172671 doi (NATIONALLICENCE)springer-10.1007/BF00172671 Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure [Elektronische Daten] [Alexander Spence, Mitchel Berger, Robert Livingston, Francis Ali-Osman, Brian Griffin] Summary: Twenty-one patients with recurrent malignant glioma who had failed prior chemotherapy with nitrosoureas were treated with high-dose intravenous cisplatin on days 1 and 8 of successive 4 week cycles. Fourteen patients were evaluable for response. Four patients showed partial responses; mean time to tumor progression (MTP) was 8 weeks. Six patients stabilized; MTP was 11 weeks. Four patients showed no response. There were no infectious or hemorrhagic complications, but partial hearing loss occurred in 7 patients and severe vomiting in 8 patients. High-dose intravenous cisplatin demonstrates substantial activity against malignant gliomas recurrent after chloroethylnitrosourea (CENU) failure. Kluwer Academic Publishers, 1992 malignant glioma nationallicence glioblastoma nationallicence brain tumors nationallicence astrocytoma nationallicence cisplatin nationallicence chemotherapy nationallicence Spence Alexander Departments of Medicine (Neurology) and Pathology (Neuropathology), University of Washington School of Medicine, 98195, Seattle, Washington, USA aut Berger Mitchel Department of Neurological Surgery, Northwest Neuro-Oncology Research and Therapy Section, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut Livingston Robert Department of Medicine (Oncology), University of Washington School of Medicine, 98195, Seattle, Washington, USA aut Ali-Osman Francis Department of Neurological Surgery, Northwest Neuro-Oncology Research and Therapy Section, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut Griffin Brian Department of Radiation Oncology, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 12/2(1992-02-01), 187-191 0167-594X 12:2<187 1992 12 11060 https://doi.org/10.1007/BF00172671 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172671 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Spence Alexander Departments of Medicine (Neurology) and Pathology (Neuropathology), University of Washington School of Medicine, 98195, Seattle, Washington, USA aut NATIONALLICENCE 700 1- Berger Mitchel Department of Neurological Surgery, Northwest Neuro-Oncology Research and Therapy Section, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut NATIONALLICENCE 700 1- Livingston Robert Department of Medicine (Oncology), University of Washington School of Medicine, 98195, Seattle, Washington, USA aut NATIONALLICENCE 700 1- Ali-Osman Francis Department of Neurological Surgery, Northwest Neuro-Oncology Research and Therapy Section, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut NATIONALLICENCE 700 1- Griffin Brian Department of Radiation Oncology, University of Washington School of Medicine, 98195, Seattle, Washington, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 12/2(1992-02-01), 187-191 0167-594X 12:2<187 1992 12 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer